Disc Medicine announced it received a Commissioner's National Priority Voucher from the US FDA for bitopertin in erythropoietic protoporphyria and submitted a New Drug Application seeking accelerated ...
Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback